Pain Management

Expert pain specialists discuss the role of combination therapy and their experience treating patients with acute pain with a multimodal approach.

Pain experts discuss the issue of substance abuse when selecting therapy for acute pain.

Drs Francesca Beaudoin, Paul Arnstein, and Jeff Gudin discuss treatment approaches to the case of a 40-year-old patient with acute pain.

Benjamin W. Friedman, MD, MS, presents a case of a 40-year-old patient with acute pain.

Is acupuncture effective in reducing pain? Can exercise help patients with fibromyalgia sleep better? New systematic review and meta-analysis provides insight.

Is acupuncture therapy effective for acute perioperative pain and acute pain in the emergency department? A review of the latest evidence, here.

A new study describes growth in prescribing of over-the-counter analgesics and other nonopioid treatments for chronic pain in the 3 years following the CDC guideline.

A new review summarized the current evidence about diagnosis and treatment of lumbar spinal stenosis. What are the key takeaways for primary care?

Dyspareunia significantly impacts quality of life for the women it affects but they may not talk about it. Answer these 10 questions about the condition and you'll be ready to ask.

Study addresses the concern that state opioid prescription laws may lead to some chronic pain patients missing out on critical pain treatment.

A cross-sectional study found that US adults with chronic pain use a variety of pain management techniques, including opioid and nondrug therapies. Key results in this 10-question quiz.

Medical cannabis is already popular with Medicare recipients and many fear insurance coverage will drive up the cost. Find out what else a new survey found.

Opioid refills were reduced by ~40% in the 9 months following an initial prescription for rimegepant among patients with migraine, a new study found.

The migraine-specific oral gepants are proving effective across the continuum of migraine frequency. Dr Gottschalk talks about their shaky start.

Findings for atogepant from the phase 3 PROGRESS study will form the basis of a submission by AbbVie to FDA for a label expansion in the US.

Consider migraine screening for all women aged 20 to 50 years, suggests Ailani; you'll likely find a majority of them have migraine. More pearls follow.

Migraine-specific preventive therapies should be in the primary care toolbox, according to headache specialist Jessica Ailani, MD.

Migraine headache specialist and researcher Jessica Ailani, MD, fully supports primary care as the setting for the majority of the treatment for the disease.

Lifetime use of opioids for migraine was found to be higher than for triptan medications. Try these 10 questions on other OVERCOME findings.

Our panel of doctors and pharmacists introduce naloxone, an opioid antagonist, as an option when treating opioid abuse or overdose.

The panel explains the common challenges they find when trying to treat a patient with opioids.

Findings on use of acute and preventive migraine therapy continue to reveal gaps with far more patients eligible than the proportions using either type.

A panel of experts discuss the parameters of the opioid epidemic and the role fentanyl plays within it.

When choosing a migraine treatment for acute attack relief, the American Headache Society suggests following these steps.

The CDC is inviting public feedback on updated recommendations for opioid prescribing for the first time since the controversial 2016 iteration.

Is virtual reality a viable option for chronic pain management? A new scoping review suggests it has potential. Here, key findings for primary care.

The American Academy of Neurology recently issued a guideline on oral and topical treatments for painful diabetic neuropathy. Here, a concise summary for clinicians.

Use of continuous glucose monitoring to assess time in target glucose range in T2D patients was evaluated in a systematic literature review covering ~14 000 participants.

Platelet-rich plasma, in theory, seems like a logical and potentially beneficial treatment for osteoarthritis. Our pain expert reviews 2 recent studies that are telling.

Intranasal CGRP inhibitor zavegepant met coprimary regulatory endpoints in pivotal phase 3 trial in adults with migraine; FDA submission planned for Q1 2022.